Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRP-AM1977X Phase I Study of Pharmacokinetics and Safety in Renal Dysfunction
jRCT2080225074Phase 1Completed
- Sponsor
- Kyorin Pharmaceutical
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lascufloxacin in chronic kidney disease (CKD) (4 arms), sponsored by Kyorin Pharmaceutical. Primary endpoint: Primary pharmacokinetic endpoints. Started Feb 2020; status: completed.
02
Drugs
lascufloxacin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080225074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225074.